Why Zevra Therapeutics Stock Zoomed 21% Higher Today
Key Points
It also posted 44% net revenue growth for the period.
Both headline figures crushed the consensus analyst estimates.
- 10 stocks we like better than Zevra Therapeutics ›
Zevra Therapeutics (NASDAQ: ZVRA) was one of the healthier companies on the stock exchange on Tuesday. Investors eagerly piled into its shares following the commercial-stage biotech's latest earnings release, leaving Zevra with a slightly over 21% gain that day.
Two convincing beats
Zevra's final set of 2025 earnings was released just after market close Monday, revealing that the company's net revenue was slightly over $34 million in the fourth quarter. That was 44% higher than the same period of 2024. Better, the company flipped to a net profit under generally accepted accounting principles (GAAP) of $12.2 million ($0.19) per share, from the year-ago loss of $35.7 million.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
This meant a crushing double beat for Zevra, as analysts tracking the stock had more modest expectations. Collectively, they were modeling barely over $28 million on the top line, and only $0.05 per share for GAAP net income.
Much of Zevra's success in the quarter (and over the course of 2025, to take a wider view) is due to the take-up of Miplyffa, its treatment for a rare neurogenerative disorder called Niemann-Pick disease. The company said the drug's availability had expanded significantly over the course of the year, reaching 68% of covered lives. During the quarter, Miplyffa's net sales rose nearly ninefold to more than $87 million.
International potential
In its earnings release, Zevra wrote that a marketing authorization application it filed for Miplyffa is under review by the European Medicines Agency, a regulatory arm of the 27-nation European Union. So, in addition to the obvious momentum Miplyffa is gathering in the U.S., it seems to have excellent potential in a large market overseas. The future looks bright for this company, and I'd say the same for its stock.
Should you buy stock in Zevra Therapeutics right now?
Before you buy stock in Zevra Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Zevra Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $530,233!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,119,682!*
Now, it’s worth noting Stock Advisor’s total average return is 955% — a market-crushing outperformance compared to 191% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of March 10, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
